Tomimaru Y - Search Results

1

Loss of exon 4 in a human T-cell factor-4 isoform promotes hepatic tumourigenicity.

Tomimaru Y, Xu CQ, Nambotin SB, Yan T, Wands JR, Kim M. Tomimaru Y, et al. Liver Int. 2013 Nov;33(10):1536-48. doi: 10.1111/liv.12189. Epub 2013 May 6. Liver Int. 2013. PMID: 23648141 Free PMC article.

2

Loss of the SxxSS motif in a human T-cell factor-4 isoform confers hypoxia resistance to liver cancer: an oncogenic switch in Wnt signaling.

Koga H, Tsedensodnom O, Tomimaru Y, Walker EJ, Lee HC, Kim KM, Yano H, Wands JR, Kim M. Koga H, et al. Among authors: tomimaru y. PLoS One. 2012;7(6):e39981. doi: 10.1371/journal.pone.0039981. Epub 2012 Jun 29. PLoS One. 2012. PMID: 22768190 Free PMC article.

3

The SxxSS motif of T-cell factor-4 isoforms modulates Wnt/β-catenin signal activation in hepatocellular carcinoma cells.

Tomimaru Y, Koga H, Shin TH, Xu CQ, Wands JR, Kim M. Tomimaru Y, et al. Cancer Lett. 2013 Aug 19;336(2):359-69. doi: 10.1016/j.canlet.2013.03.031. Epub 2013 Apr 2. Cancer Lett. 2013. PMID: 23562475 Free PMC article.

4

Upregulation of T-cell factor-4 isoform-responsive target genes in hepatocellular carcinoma.

Tomimaru Y, Koga H, Yano H, de la Monte S, Wands JR, Kim M. Tomimaru Y, et al. Liver Int. 2013 Aug;33(7):1100-12. doi: 10.1111/liv.12188. Epub 2013 May 8. Liver Int. 2013. PMID: 23651211 Free PMC article.

5

A Novel Drug, CC-122, Inhibits Tumor Growth in Hepatocellular Carcinoma through Downregulation of an Oncogenic TCF-4 Isoform.

Tomimaru Y, Aihara A, Wands JR, Aloman C, Kim M. Tomimaru Y, et al. Transl Oncol. 2019 Oct;12(10):1345-1356. doi: 10.1016/j.tranon.2019.07.002. Epub 2019 Jul 25. Transl Oncol. 2019. PMID: 31352197 Free PMC article.

6

Functional consequences of WNT3/Frizzled7-mediated signaling in non-transformed hepatic cells.

Nambotin SB, Tomimaru Y, Merle P, Wands JR, Kim M. Nambotin SB, et al. Among authors: tomimaru y. Oncogenesis. 2012 Oct 22;1(10):e31. doi: 10.1038/oncsis.2012.31. Oncogenesis. 2012. PMID: 23552403 Free PMC article.

7

Tumor progression-related transmembrane protein aspartate-β-hydroxylase is a target for immunotherapy of hepatocellular carcinoma.

Shimoda M, Tomimaru Y, Charpentier KP, Safran H, Carlson RI, Wands J. Shimoda M, et al. Among authors: tomimaru y. J Hepatol. 2012 May;56(5):1129-1135. doi: 10.1016/j.jhep.2011.12.016. Epub 2012 Jan 13. J Hepatol. 2012. PMID: 22245894 Free PMC article.

8

Aspartate-β-hydroxylase induces epitope-specific T cell responses in hepatocellular carcinoma.

Tomimaru Y, Mishra S, Safran H, Charpentier KP, Martin W, De Groot AS, Gregory SH, Wands JR. Tomimaru Y, et al. Vaccine. 2015 Mar 3;33(10):1256-66. doi: 10.1016/j.vaccine.2015.01.037. Epub 2015 Jan 25. Vaccine. 2015. PMID: 25629522 Free PMC article.

9

Circulating microRNA-21 as a novel biomarker for hepatocellular carcinoma.

Tomimaru Y, Eguchi H, Nagano H, Wada H, Kobayashi S, Marubashi S, Tanemura M, Tomokuni A, Takemasa I, Umeshita K, Kanto T, Doki Y, Mori M. Tomimaru Y, et al. J Hepatol. 2012 Jan;56(1):167-75. doi: 10.1016/j.jhep.2011.04.026. Epub 2011 Jul 13. J Hepatol. 2012. PMID: 21749846

10

IGFBP7 downregulation is associated with tumor progression and clinical outcome in hepatocellular carcinoma.

Tomimaru Y, Eguchi H, Wada H, Kobayashi S, Marubashi S, Tanemura M, Umeshita K, Kim T, Wakasa K, Doki Y, Mori M, Nagano H. Tomimaru Y, et al. Int J Cancer. 2012 Jan 15;130(2):319-27. doi: 10.1002/ijc.25994. Epub 2011 Apr 13. Int J Cancer. 2012. PMID: 21328580

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

277 results

Search Page

Filters